Pacific Biosciences of California (PACB) Analysts Cut Targets and Flag Risks Ahead of New Competitive Launches

Pacific Biosciences of California (PACB) is facing challenges as analysts cut price targets to $1.50 from $2 and flag risks in demand for sequencing consumables, growth visibility, and potential pauses in orders ahead of new competitive launches. Barclays downgraded PACB to Underweight from Equal Weight and trimmed its target to $1.50 from $2. The company is tied to broader sequencing trends, with upcoming competitive launches and SPRQ NX being key events.